The study investigates the effects of a combinational therapy of Capecitabine (1000 mg/m2 bid per os), deep radiofrequency oncological hyperthermia for a patient with stomach cancer by gastroscopy. As a result The disease went into complete remission and the report presented describes an unusual and very favorable clinical history. It had remarkable success with this protocol without using invasive surgical or laparoscopic HIPEC application.
72 year-old male patient was diagnosed with stomach cancer by gastroscopy in 2009 May. The patient performed a partial gastric resection not followed by adjuvant chemotherapy as the removed locoregional lymph nodes were disease-free, and there was no evidence of spreading disease in other body regions.
In November 2009, he began malaise, progressive weight loss, loss of appetite, abdominal pain until he came to emergency surgery for intestinal obstruction. The surgeon detected extensive peritoneal carcinomatosis, and although he had made a necessary temporal restore, he made a poor prognosis and predicted a very short survival. The patient came to the attention for supportive and palliative care.
The therapy set at that moment was a combination of Capecitabine (1000 mg/m2 bid per os), deep radiofrequency oncological hyperthermia (Oncotherm EHY-3010 ML device) twice a week for one hour without rest and three hours whole-body infrared hyperthermia (Heckel HT 3000 device) for five consecutive days for a month.
The disease went into complete remission. The patient gained his weight by eight kg, had good and has continued appetite, with significantly improved quality of life. A CT scan documented the remission with contrast. The therapy continued for eighteen months with persistent remission. After eighteen months, a resurgence of the disease occurred, which proved intractable and led to death after three months.
The case report presented describes an unusual and very favorable clinical history. This had remarkable success with this protocol without using invasive surgical or laparoscopic HIPEC application. This case report may suggest a new approach to peritoneal disseminated cancer pathology and indeed may be the starting point to investigate further the effectiveness of this complex therapy protocol in other tumors with peritoneal dissemination.